

Aromatasehemmer und Osteoporose - Les Inhibiteurs de l'Aromatase et l'Ostéoporose

Referenzen - Références:

1. Thuerlimann B, Koeberle D, Senn HJ. Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations. *Eur J Cancer* 2007; 43:46-52.
 2. Eastell R. Breast cancer and the risk of osteoporotic fracture: A paradox. *J Clin Endocrinol Metab* 2007; 92:42-3.
 3. Sasano H, Uzuki M, Sawai T, et al. Aromatase in human bone tissue. *J Bone Miner Res* 1997; 12:1416-23.
 4. Shozu M, Simpson ER. Aromatase expression of human osteoblast-like cells. *Mol Cell Endocrinol* 1998; 139:117-29.
 5. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. *J Clin Oncol* 2006; 24:5305-12.
 6. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. *J Clin Oncol* 2005; 23:5126-37.
 7. Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, di Salle E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. *J Steroid Biochem* 1988; 30:391-4.
 8. Kraenzlin ME. Biochemical markers of bone turnover and osteoporosis management. *Eur Musculoskeletal Rev* 2007; in print.
 9. Meier C, Seibel MJ. Biochemische Knochenbaumarke bei Knochenmetastasen. *Onkologie* 2006:34-39.
 10. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). *J Bone Miner Res* 2006; 21:1215-23.
 11. Bajetta E, Zilembo N, Bichisao E. Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact. *J Clin Oncol* 2002; 20:3039-40; author reply 3040.
 12. Pecherstorfer M, Zimmer-Roth I, Schilling T, et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. *J Clin Endocrinol Metab* 1995; 80:97-103.
 13. Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton LJ, 3rd, Riggs BL. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. *J Bone Miner Res* 2002; 17:172-8.
 14. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. *J Clin Oncol* 2006; 24:3629-35.
 15. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. *Cancer Epidemiol Biomarkers Prev* 2002; 11:614-21.
 16. Goss PE, Qi S, Josse RG, et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. *Bone* 2004; 34:384-92.
 17. Goss PE, Thomsen T, Banke-Bonchita J. A randomized, placebo-controlled explorative study to investigate the effect of low estrogen plasma levels on markers of bone turnover in healthy postmenopausal women during the 12-week treatment with exemestane or letrozole. *Breast Cancer Res Treat* 2002; 76(S76).
 18. Subar M, Thomsen T, Banke-Bonchita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover and lipid metabolism in healthy volunteers. *J Clin Oncol* 2004; 23(7385).
 19. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. *Lancet Oncol* 2007; 8:119-27.
 20. McCloskey E, Hannon R, Lakner G, Clack G, A. M, Eastell R. The letrozole, exemestane and anastrozole pharmacodynamics (LEAP) trial: A direct comparison of bone biochemical measurements between aromatase inhibitors in healthy postmenopausal women. *J Clin Oncol* 2006; 24(18S):555.
 21. McCloskey E. Effects of third-generation aromatase inhibitors on bone. *Eur J Cancer* 2006; 42:1044-51.
 22. Gonnelli S, Cadirni A, Caffarelli C, et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. *Bone* 2007; 40:205-10.
 23. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. *Lancet* 2005; 365:60-2.
-

Aromatasehemmer und Osteoporose - Les Inhibiteurs de l'Aromatase et l'Ostéoporose

Referenzen - Références:

24. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. *N Engl J Med* 2004; 350:1081-92.
 25. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. *N Engl J Med* 2005; 353:2747-57.
 26. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. *J Clin Oncol* 2007; 25:486-92.
 27. Eastell R. Aromatase inhibitors and bone. *J Steroid Biochem Mol Biol* 2007.
 28. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. *N Engl J Med* 2003; 349:1793-802.
 29. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. *J Clin Oncol* 2003; 21:4042-57.
 30. Kraenzlin ME, Seibel MJ, Meier C. Diagnostik und Therapie der Osteoporose. Teil 1: Diagnostik und Frakturrisikoevaluation. *Schweiz Med Forum* 2006; 6:712-717.
 31. Meier C, Seibel MJ, Kraenzlin ME. Diagnostik und Therapie der Osteoporose. Teil 2: Präventive und therapeutische Massnahmen. *Schweiz Med Forum* 2006; 6:735-744.
 32. Greenspan SL, Bhattacharya RK, Sereika SM, Brufsky A, Vogel VG. Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. *J Clin Endocrinol Metab* 2007; 92:131-6.
 33. Fuleihan GH, Salamoun M, Mourad YA, et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. *J Clin Endocrinol Metab* 2005; 90:3209-14.
 34. Vehmanen L, Saarto T, Risteli J, Risteli L, Blomqvist C, Elomaa I. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. *Breast Cancer Res Treat* 2004; 87:181-8.
 35. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. *J Clin Oncol* 2007; 25:829-36.
-